Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

Director, Head of IR, PR & Marketing, Arcturus Therapeutics Holdings Inc ... and neutralizing antibody responses, and specific T cell activation following single dose administration.

In this article, we are going to take a look at where Arcturus Therapeutics Holdings ... even if Wood hadn’t bought additional shares, her original holdings would currently be worth $62.7 ...

Arcturus Therapeutics Holdings Inc. (the “Company ... which included more than 20,000 participants and dose ranges from 1 to 20 mcg of mRNA. “Clinically validating our low-dose STARR ...

BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a ...

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154 ...

Fintel reports that on January 28, 2025, BTIG initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Buy recommendation. As of December 23, 2024, the average one-year price ...

Arcturus Therapeutics Holdings Inc. (NASDAQ ... For more information see our T&C.

TOKYO, January 31, 2025--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that it has received approval for a ...